Pennsylvania-based Egalet Corporation has announced that it will begin promoting Sprix ketorolac tromethamine nasal spray in the second quarter of 2015. Sprix is a non-steroidal anti-inflammatory drug (NSAID) for the short-term treatment of moderate to moderately severe pain, which was acquired by Egalet from Daiichi Sankyo subsidiary Luitpold Pharmaceuticals earlier this year.
Sprix was developed by Roxro and approved by the FDA in 2010. Luitpold acquired Roxro later that year.
Read the Egalet press release.
